DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 16350.0
(-1.57%)
KRW 16350.0
(-1.57%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 47.17 Billion KRW | -10.82% |
| 2022 | 52.89 Billion KRW | 5.07% |
| 2021 | 50.34 Billion KRW | -9.98% |
| 2020 | 55.92 Billion KRW | -0.69% |
| 2019 | 56.31 Billion KRW | 19.94% |
| 2018 | 46.94 Billion KRW | 18.55% |
| 2017 | 39.6 Billion KRW | -2.6% |
| 2016 | 40.65 Billion KRW | 48.25% |
| 2015 | 27.42 Billion KRW | 29.99% |
| 2014 | 21.09 Billion KRW | 25.86% |
| 2013 | 16.76 Billion KRW | -24.87% |
| 2012 | 22.31 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 13.6 Billion KRW | -30.85% |
| 2024 Q1 | 19.68 Billion KRW | 117.11% |
| 2023 Q2 | 9.94 Billion KRW | -37.99% |
| 2023 FY | 47.17 Billion KRW | -10.82% |
| 2023 Q4 | 9.06 Billion KRW | -25.29% |
| 2023 Q3 | 12.13 Billion KRW | 22.05% |
| 2023 Q1 | 16.03 Billion KRW | 71.21% |
| 2022 Q4 | 9.36 Billion KRW | -20.75% |
| 2022 Q3 | 11.81 Billion KRW | -26.21% |
| 2022 Q2 | 16.01 Billion KRW | 2.01% |
| 2022 Q1 | 15.69 Billion KRW | 1.86% |
| 2022 FY | 52.89 Billion KRW | 5.07% |
| 2021 Q2 | 11.32 Billion KRW | -25.13% |
| 2021 Q1 | 15.12 Billion KRW | 67.84% |
| 2021 Q4 | 15.41 Billion KRW | 81.66% |
| 2021 Q3 | 8.48 Billion KRW | -25.08% |
| 2021 FY | 50.34 Billion KRW | -9.98% |
| 2020 Q2 | 13.35 Billion KRW | -19.23% |
| 2020 Q4 | 9.01 Billion KRW | -47.06% |
| 2020 FY | 55.92 Billion KRW | -0.69% |
| 2020 Q1 | 16.53 Billion KRW | -0.32% |
| 2020 Q3 | 17.02 Billion KRW | 27.46% |
| 2019 Q2 | 12.14 Billion KRW | -2.73% |
| 2019 FY | 56.31 Billion KRW | 19.94% |
| 2019 Q1 | 12.48 Billion KRW | -11.27% |
| 2019 Q4 | 16.58 Billion KRW | 9.92% |
| 2019 Q3 | 15.09 Billion KRW | 24.25% |
| 2018 Q2 | 10.68 Billion KRW | 3.95% |
| 2018 Q4 | 14.07 Billion KRW | 18.14% |
| 2018 Q3 | 11.91 Billion KRW | 11.48% |
| 2018 FY | 46.94 Billion KRW | 18.55% |
| 2018 Q1 | 10.27 Billion KRW | -19.81% |
| 2017 Q1 | 8.18 Billion KRW | -27.48% |
| 2017 Q4 | 12.81 Billion KRW | 41.03% |
| 2017 Q3 | 9.08 Billion KRW | -4.4% |
| 2017 Q2 | 9.5 Billion KRW | 16.15% |
| 2017 FY | 39.6 Billion KRW | -2.6% |
| 2016 FY | 40.65 Billion KRW | 48.25% |
| 2016 Q2 | 9.93 Billion KRW | 17.91% |
| 2016 Q1 | 8.42 Billion KRW | -3.48% |
| 2016 Q4 | 11.28 Billion KRW | 2.47% |
| 2016 Q3 | 11.01 Billion KRW | 10.9% |
| 2015 Q2 | 5.22 Billion KRW | -2.46% |
| 2015 Q1 | 5.36 Billion KRW | 20.7% |
| 2015 Q3 | 8.1 Billion KRW | 55.02% |
| 2015 Q4 | 8.72 Billion KRW | 7.67% |
| 2015 FY | 27.42 Billion KRW | 29.99% |
| 2014 Q3 | 6.34 Billion KRW | 36.21% |
| 2014 Q4 | 4.44 Billion KRW | -30.02% |
| 2014 FY | 21.09 Billion KRW | 25.86% |
| 2014 Q1 | 5.64 Billion KRW | 289.54% |
| 2014 Q2 | 4.65 Billion KRW | -17.51% |
| 2013 Q4 | 1.45 Billion KRW | -79.57% |
| 2013 FY | 16.76 Billion KRW | -24.87% |
| 2013 Q1 | 4.86 Billion KRW | -27.64% |
| 2013 Q2 | 3.35 Billion KRW | -31.01% |
| 2013 Q3 | 7.09 Billion KRW | 111.74% |
| 2012 FY | 22.31 Billion KRW | 0.0% |
| 2012 Q4 | 6.71 Billion KRW | -7.67% |
| 2012 Q3 | 7.27 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.42 Billion KRW | 342.828% |
| CMG Pharmaceutical Co., Ltd. | 6.45 Billion KRW | -630.792% |
| Celltrion Pharm, Inc. | 21.26 Billion KRW | -121.844% |
| Huons Global Co., Ltd. | 38.38 Billion KRW | -22.904% |
| Enzychem Lifesciences Corporation | -9.32 Billion KRW | 605.824% |
| Humedix Co., Ltd. | 24.82 Billion KRW | -90.064% |
| Boditech Med Inc. | 25.94 Billion KRW | -81.816% |
| EuBiologics Co., Ltd. | -13.87 Billion KRW | 439.904% |
| FutureChem Co.,Ltd | -6.7 Billion KRW | 803.169% |
| Huons Co., Ltd. | 50.47 Billion KRW | 6.534% |
| BNC Korea Co., Ltd. | 25.68 Billion KRW | -83.661% |
| AptaBio Therapeutics Inc. | -12.06 Billion KRW | 491.118% |